NCT00534833View on ClinicalTrials.gov

Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™

PHASE3CompletedINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

March 31, 2009

Conditions
DiphtheriaTetanusPertussisHepatitis BHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

DTaP-HB-PRP~T vaccine

0.5 mL, Intramuscular

BIOLOGICAL

Tritanrix-HepB/Hib™

0.5 mL, Intramuscular

BIOLOGICAL

Oral Polio Vaccine

0.5 mL, Oral

Trial Locations (2)

Unknown

Manila

Quezon City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ | Biotech Hunter | Biotech Hunter